Parties now operate as one unified supply platform
Leading global healthcare services provider Uniphar announces a strategic merger between Uniphar Clinical and BMclinical, reinforcing Uniphar Clinical’s integrated clinical supply offering and solidifying its position as a trusted partner to pharmaceutical and biotech companies worldwide.
As part of Uniphar’s global platform supporting the full product lifecycle – from early clinical development through to commercialisation and beyond. Uniphar Clinical leverages scalable infrastructure and expertise to provide bespoke packaging, labeling, storage and distribution solutions, while BMclinical brings extensive experience in comparator sourcing and clinical trial supply.
The combined Uniphar Clinical offering will streamline clinical supply chains, minimise execution risk, and ensure continuity from study initiation through to completion, helping sponsors deliver therapies to patients faster. In addition, this broader offering enhances Uniphar’s ability to support partners across every stage of development, capitalising on the scale and efficiency of a unified global sourcing model.
“As global trials become more complex, sponsors increasingly value partners who can combine scale with specialist expertise,” said Dermot Ryan, Chief Operating Officer at Uniphar. “By aligning BMclinical’s sourcing capabilities with Uniphar Clinical’s integrated platform, we provide a comprehensive suite of clinical services based on agility and dependability that set a new standard for our partners and ultimately accelerate patient access to critical therapies.”
Integrated services
Building on Uniphar Clinical’s and BMclinical’s combined expertise, the new partnership offers a comprehensive range of integrated services designed to support every stage of clinical trial supply, including: commercial drug supply capability including global sourcing of comparators; packaging and labeling services spanning both primary and secondary clinical packaging; global storage and distribution capabilities, including compliant facilities equipped with real-time temperature monitoring; and overage management solutions.
With strategically located GMP- and GDP-compliant flagship facilities in Lelystad, the Netherlands, and Raleigh, North Carolina, alongside a distribution footprint spanning Europe, North America, APAC, and MENA, the partnership is positioned to deliver temperature-sensitive clinical materials reliably, wherever trials are underway.
Shanelle Austin-Mehta, Director of Uniphar | Clinical said: “Bringing the expertise of Uniphar Clinical and BMclinical together creates an unparalleled service offering to the pharmaceutical and biotech industry – one designed to anticipate challenges and provide the reliability sponsors need to keep studies on track.”
